BCM
ACHN

Bayesian Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Bayesian Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-45,106
Closed -$203K – 796
2017
Q3 		$203K Buy
+45,106
New +$200K 0.05% 428

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Bayesian Capital Management's ACHN Position: Q4 2017 in Review

Bayesian Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q4 2017, closing a stake of 45,106 shares — an estimated $203K sold.

Bayesian Capital Management first reported a position in ACHN in Q3 2017 and held it in 1 quarter. The position peaked at $203K in Q3 2017. 149 funds tracked by Wall St. Rank hold ACHN as of Q4 2017.

  • Bayesian Capital Management reported no remaining Achillion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Bayesian Capital Management sold 45,106 Achillion Pharmaceuticals shares in Q4 2017, an estimated $203K.
  • Bayesian Capital Management first reported a position in Achillion Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Bayesian Capital Management's Achillion Pharmaceuticals position peaked at $203K in Q3 2017.
  • 149 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2017.

Based on Bayesian Capital Management's 13F filing for Q4 2017, filed 12 Feb 2018.